0001193125-23-250341.txt : 20231004 0001193125-23-250341.hdr.sgml : 20231004 20231004070030 ACCESSION NUMBER: 0001193125-23-250341 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231002 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 231306559 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 8-K 1 d547449d8k.htm 8-K 8-K
false 0001609809 0001609809 2023-10-02 2023-10-02












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2023




(Exact name of Registrant as Specified in Its Charter)




Delaware   001-37465   27-4326290

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


200 Sidney Street - 4th Floor

Cambridge, MA

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common stock, par value $0.001 per share   MCRB  

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

On October 2, 2023, Grégory Behar informed Seres Therapeutics, Inc. (the “Company”) of his resignation from the board of directors of the Company, effective immediately, in connection with his resignation from Nestlé Health Science.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: October 4, 2023     By:  

/s/ Thomas J. DesRosier

    Name:   Thomas J. DesRosier
    Title:   Chief Legal Officer and Executive Vice President
EX-101.SCH 2 mcrb-20231002.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 mcrb-20231002_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 mcrb-20231002_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 02, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001609809
Document Type 8-K
Document Period End Date Oct. 02, 2023
Entity Registrant Name SERES THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37465
Entity Tax Identification Number 27-4326290
Entity Address, Address Line One 200 Sidney Street - 4th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 945-9626
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol MCRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d547449d8k_htm.xml IDEA: XBRL DOCUMENT 0001609809 2023-10-02 2023-10-02 false 0001609809 8-K 2023-10-02 SERES THERAPEUTICS, INC. DE 001-37465 27-4326290 200 Sidney Street - 4th Floor Cambridge MA 02139 (617) 945-9626 false false false false Common stock, par value $0.001 per share MCRB NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d547449d8k.htm mcrb-20231002.xsd mcrb-20231002_lab.xml mcrb-20231002_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d547449d8k.htm": { "nsprefix": "mcrb", "nsuri": "http://serestherapeutics.com/20231002", "dts": { "inline": { "local": [ "d547449d8k.htm" ] }, "schema": { "local": [ "mcrb-20231002.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "mcrb-20231002_lab.xml" ] }, "presentationLink": { "local": [ "mcrb-20231002_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-10-02_to_2023-10-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d547449d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-10-02_to_2023-10-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d547449d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://serestherapeutics.com//20231002/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0001193125-23-250341-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-250341-xbrl.zip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

74J+]06B5!IXCFX0Q1]OP M C

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